dc.contributor.author | Alquezar Artieda, Natividad | |
dc.contributor.author | Kužílková, Daniela | |
dc.contributor.author | Roberts, Jennie | |
dc.contributor.author | Hložková, Kateřina | |
dc.contributor.author | Pecinova, Alena | |
dc.contributor.author | Pecina, Petr | |
dc.contributor.author | Zwyrtková, Martina | |
dc.contributor.author | Potůčková, Eliška | |
dc.contributor.author | Kavan, Daniel | |
dc.contributor.author | Heřmanová, Ivana | |
dc.contributor.author | Žaliová, Markéta | |
dc.contributor.author | Novák, Petr | |
dc.contributor.author | Mracek, Tomas | |
dc.contributor.author | Šrámková, Lucie | |
dc.contributor.author | Tennant, Daniel A | |
dc.contributor.author | Trka, Jan | |
dc.contributor.author | Starková, Júlia | |
dc.date.accessioned | 2023-09-21T11:10:24Z | |
dc.date.available | 2023-09-21T11:10:24Z | |
dc.date.issued | 2023 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14178/2028 | |
dc.description.abstract | L-asparaginase (ASNase), the drug included on the World Health Organization's List of EssentialMedicines, is irreplaceable in the front-line treatment of childhood acute lymphoblastic leukemia(ALL)1 . However, the relapse of ALL is often associated with resistance to ASNase and itsmechanisms are not fully understood. The cytotoxic effect of ASNase relies on depleting exogenousasparagine (Asn) and glutamine (Gln), inducing apoptosis in leukemic cells because of their reducedcapability of Asn synthesis. Our previous in vitro data demonstrated that ASNase triggers metabolicreprogramming of leukemic cells which impedes the anti-leukemic effect. Metabolic processes ofleukemic cells have been shown to be altered by the environment of the bone marrow (BM) whichmay contribute to chemoresistance. Herein, we investigated the impact of BM attributes oncellular metabolic processes of leukemic cells in order to demonstrate the more complex picture ofASNase-driven metabolic rewiring and its role in the mechanism of resistance. | en |
dc.language.iso | en | |
dc.relation.url | https://doi.org/10.1182/bloodadvances.2021006431 | |
dc.rights | Creative Commons Uveďte původ-Neužívejte dílo komerčně-Nezpracovávejte 4.0 International | cs |
dc.rights | Creative Commons Attribution-NonCommercial-NoDerivativeWorks 4.0 International | en |
dc.title | Restored biosynthetic pathways induced by MSCs serve as rescue mechanism in leukemia cells after L-asparaginase therapy | en |
dcterms.accessRights | restrictedAccess | |
dcterms.license | https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode | |
dc.date.updated | 2025-01-15T10:11:42Z | |
dc.subject.keyword | L-asparaginase | en |
dc.subject.keyword | hildhood acute lymphoblastic leukemia | en |
dc.subject.keyword | asparagine | en |
dc.subject.keyword | glutamine | en |
dc.subject.keyword | bone marrow | en |
dc.identifier.eissn | 2473-9537 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//LX22NPO5102 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/GA0/GA/GA20-27132S | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/GAUK/GAUK794218 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/FN/I-FN/I-FNM | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/COOP/COOP | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/GA0/GA/GA20-27132S | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/GA0/GA/GA20-27132S | |
dc.date.embargoStartDate | 2025-01-15 | |
dc.type.obd | 73 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | |
dc.identifier.doi | 10.1182/bloodadvances.2021006431 | |
dc.identifier.utWos | 001002224300001 | |
dc.identifier.eidScopus | 2-s2.0-85162919169 | |
dc.identifier.obd | 618216 | |
dc.identifier.riv | RIV/00216208:11130/23:10450557 | |
dc.identifier.pubmed | 36399517 | |
dc.subject.rivPrimary | 30000::30200::30205 | |
dc.subject.rivSecondary | 30000::30200::30204 | |
dcterms.isPartOf.name | Blood Advances | |
dcterms.isPartOf.issn | 2473-9529 | |
dcterms.isPartOf.journalYear | 2023 | |
dcterms.isPartOf.journalVolume | 7 | |
dcterms.isPartOf.journalIssue | 10 | |
uk.faculty.primaryId | 109 | |
uk.faculty.primaryName | 2. lékařská fakulta | cs |
uk.faculty.primaryName | Second Faculty of Medicine | en |
uk.faculty.secondaryId | 52 | |
uk.faculty.secondaryName | Fakultní nemocnice v Motole | cs |
uk.faculty.secondaryName | Motol University Hospital | en |
uk.department.primaryId | 109 | |
uk.department.primaryName | 2. lékařská fakulta | cs |
uk.department.primaryName | Second Faculty of Medicine | en |
uk.department.secondaryId | 1675 | |
uk.department.secondaryId | 100010692507 | |
uk.department.secondaryName | Klinika dětské hematologie a onkologie | cs |
uk.department.secondaryName | Klinika dětské hematologie a onkologie | en |
uk.department.secondaryName | Klinika dětské hematologie a onkologie 2. LF UK a FN Motol | cs |
uk.department.secondaryName | Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine and Motol University Hos | en |
dc.description.pageRange | 2228-2236 | |
dc.type.obdHierarchyCs | ČLÁNEK V ČASOPISU::článek v časopisu::letter to the editors | cs |
dc.type.obdHierarchyEn | JOURNAL ARTICLE::journal article::letter to the editors | en |
dc.type.obdHierarchyCode | 73::152::233 | en |
uk.displayTitle | Restored biosynthetic pathways induced by MSCs serve as rescue mechanism in leukemia cells after L-asparaginase therapy | en |